Verbeek R, Stoekenbroek RM, Hovingh GK. PCSK9 inhibitors: Novel therapeutic agents for the treatment of hypercholesterolemia. Eur J Pharmacol. 2015 May 16. [Epub ahead of print]
Giugliano RP, Sabatine MS. Are PCSK9 inhibitors the next breakthrough in the cardiovascular field? J Am Coll Cardiology. 2015;65(24):2638-2651.
Abifadel M, Elbitar S, El Khoury P, et al. Living the PCSK9 adventure: from the identification of a new gene in familial hypercholesterolemia towards a potential new class of anticholesterol drugs. Curr Atheroscler Rep. 2014;16(9):439.
Timms KM, Wagner S, Samuels ME, et al. A mutation in PCSK9 causing autosomal-dominant hypercholesterolemia in a Utah pedigree. Hum Genet 2004; 114:349-353.
Lowe DC, Vaughan TJ. Rheumatology: a force for change in monoclonal antibodies. Curr Pharm Des. 2015;21(17):2179-2186.
Nelson PN, Reynolds GM, Waldron EE, Ward E, Giannopoulos K, Murray PG. Demystified. Mol Pathol..2000; 53(3):111–117.
Navarese EP, Kołodziejczak M, Schulze V, et al. Effects of proprotein convertase subtilisin/kexin type 9 antibodies in adults with hypercholesterolemia. A systematic review and meta-analysis. Ann Intern Med. 2015; 163:40-51.
Cainzos-Achirica M, Martin SS, Cornell JE, et al. PHPCSK9 Inhibitors: A New Era in Lipid-Lowering Treatment? Ann Intern Med. 2015;163(1):64-65.
United States National Institutes of Health. Clinical Trials.gov. ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553 (REGN727). Available at: https://clinicaltrials.gov/ct2/show/NCT01663402. Accessed: August 4, 2015.